Cell Therapy News

Researchers have identified CD58 status as a predictive marker for durable responses to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.

An off-the-shelf, virus-specific T-cell therapy demonstrated proof of concept to enter a clinical trial for the treatment of severe COVID-19 infection, according to study results presented at the virtual ASH Annual Meeting and Exposition.

More than 90% of patients with advanced-stage indolent non-Hodgkin lymphoma had an objective response to treatment with axicabtagene ciloleucel, according to data presented at the virtual ASH Annual Meeting and Exposition.

Several oncology researchers received the NIH Director’s New Innovator Award.

The Society for Immunotherapy of Cancer created the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund.

Ten years ago, researchers at NCI reported use of CD19-directed chimeric antigen receptor T-cell therapy that successfully induced remission in a patient with follicular lymphoma.

Late effects of pediatric cancer treatment may not be readily apparent to primary care clinicians or specialists who follow childhood cancer survivors over the long term.

The combination of an investigational cell therapy using tumor-infiltrating lymphocytes and pembrolizumab induced responses among a small cohort of patients with metastatic head and neck squamous cell carcinoma, study results showed.

The combination of an investigational cell therapy using tumor-infiltrating lymphocytes and pembrolizumab induced responses among a small cohort of patients with metastatic head and neck squamous cell carcinoma, study results showed.

The FDA lifted its clinical hold on a study evaluating UCARTCS1 for the treatment of patients with relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.